PGT: Preimplantation genetic screening

PGT-M can be used to rule out virtually any rare inherited disease (recessively hereditary, dominantly hereditary, even sex-linked). The most common rare diseases here are:

• cystic fibrosis,
• spinal muscular atrophy,
• metabolic disorders,
• neurofibromatosis,
• Marfan syndrome,
• Huntington’s chorea,
• familial hypercholesterolemia,
• Fragile X syndrome,
• muscular dystrophy syndrome,
• hereditary breast and ovarian cancers (BRCA1 and BRCA2).

Unfortunately, partners most often learn about the genetic burden only after the birth of a sick child. However, there are ways to avoid this occurring or to find out your genetic predispositions in advance.

You can test your genes and disposition for hereditary diseases at Repromeda using PANDA predictive genetic testing.

No, it isn’t. PGT significantly helps the birth of babies free of genetic burdens and the success rate of transfers continues to grow. In indicated cases, PGT is also paid for by the insurance company.

Biopsy of the embryo will not affect the future baby in any way. Here are three reasons why you have nothing to worry about.

1. Biopsy is performed from the trophectoderm. This is the part of the embryo from which the fetal membranes subsequently emerge, not the fetus itself.
2. During the biopsy, a very small number of cells are taken. Moreover, when they are taken, the embryo is at a stage when the cells are multiplying very rapidly.
3. The biopsy is performed by our top embryologists, who themselves train embryologists around the world and have the highest possible qualifications.

For reliable PGT results we biopsy embryos on the 5th to 6th day of development. However, the appropriate time for transfer to the uterus is also 5th to 6th day of development, and it is not possible to perform genetic testing and transfer at the same time. Here at Repromeda we rely on cryoembryo transfer, which allows us to genetically examine the embryo and at the same time yields convincing results.

Unfortunately not. PGT requires cells collected from embryos. We cannot get the sample we need in the case of spontaneous conception. If pregnancy is already underway, prenatal testing is the only option. In this case, however, it is necessary to take into account the possible decision to terminate the pregnancy due to a genetic defect or the risk of giving birth to an affected child.

None. PGD, or Preimplantation Genetic Diagnosis, is an older – no longer used – term for PGT, or Preimplantation Genetic Testing.

PGT-M can be used to rule out virtually any rare inherited disease (recessively hereditary, dominantly hereditary, even sex-linked). The most common rare diseases here are:

• cystic fibrosis,
• spinal muscular atrophy,
• metabolic disorders,
• neurofibromatosis,
• Marfan syndrome,
• Huntington’s chorea,
• familial hypercholesterolemia,
• Fragile X syndrome,
• muscular dystrophy syndrome,
• hereditary breast and ovarian cancers (BRCA1 and BRCA2).

Unfortunately, partners most often learn about the genetic burden only after the birth of a sick child. However, there are ways to avoid this occurring or to find out your genetic predispositions in advance.

You can test your genes and disposition for hereditary diseases at Repromeda using PANDA predictive genetic testing.

Biopsy of the embryo will not affect the future baby in any way. Here are three reasons why you have nothing to worry about.

1. Biopsy is performed from the trophectoderm. This is the part of the embryo from which the fetal membranes subsequently emerge, not the fetus itself.
2. During the biopsy, a very small number of cells are taken. Moreover, when they are taken, the embryo is at a stage when the cells are multiplying very rapidly.
3. The biopsy is performed by our top embryologists, who themselves train embryologists around the world and have the highest possible qualifications.

For reliable PGT results we biopsy embryos on the 5th to 6th day of development. However, the appropriate time for transfer to the uterus is also 5th to 6th day of development, and it is not possible to perform genetic testing and transfer at the same time. Here at Repromeda we rely on cryoembryo transfer, which allows us to genetically examine the embryo and at the same time yields convincing results.

Unfortunately not. PGT requires cells collected from embryos. We cannot get the sample we need in the case of spontaneous conception. If pregnancy is already underway, prenatal testing is the only option. In this case, however, it is necessary to take into account the possible decision to terminate the pregnancy due to a genetic defect or the risk of giving birth to an affected child.